agents that affect bone mineral homeostasis n.
Skip this Video
Loading SlideShow in 5 Seconds..
Agents That Affect Bone Mineral Homeostasis PowerPoint Presentation
Download Presentation
Agents That Affect Bone Mineral Homeostasis

Agents That Affect Bone Mineral Homeostasis

167 Views Download Presentation
Download Presentation

Agents That Affect Bone Mineral Homeostasis

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Agents That Affect Bone Mineral Homeostasis • Functions of the bone: • Principal structural support for the body • Ca and PO4 reservoir • Space for hematopoesis

  2. Two hormones serve as principal regulators of Ca & P homeostasis: parathyroid hormone (PTH) & vitamin D (active metabolite) • Certain of secondary regulators— calcitonin, glucocorticoids & estrogens—are useful therapeutically

  3. Some mechanisms contributing to bone mineral homeostasis.

  4. CLINICAL PHARMACOLOGY Conditions that alter bone mineral homeostasis: Effects on bone can result in: • osteoporosis (abnormal loss of bone; remaining bone histologically normal) • osteomalacia (abnormal bone formation due to inadequate mineralization) • osteitisfibrosa (excessive bone resorption with fibrotic replacement of resorption cavities)

  5. OsteomalaciaOsteitisfibrosacystica


  7. HYPERCALCEMIA • Hypercalcemiacauses CNS depression, including coma, & is potentially lethal • Arrhythmia cardiovascular collapse give MgSO4 (IV) to offset the dynamic effect • Major causes (other than thiazide therapy) are hyperparathyroidism & cancer with or without bone metastases • Less common causes are hypervitaminosis D, sarcoidosis, thyrotoxicosis, milk-alkali syndrome - seldom require emergency ↓ of serum Ca (with exception of hypervitaminosis D) • Ca X PO4 must be < 55 mg2/dL2 in order to prevent ectopic calcification in soft vital tissues

  8. Treatment of hypercalcemia 1. Saline Diuresis500-1000 mL/h of saline to reverse dehydration & restore urine flow + loop diuretic to ↑urine flow but also ↓Careabsorption in ascending limb of loop of Henle 2. If more prolonged treatment of hypercalcemia is required:1. BisphosphonatesEtidronate in saline IV for 3 days. Pamidronate appears to be more effective

  9. Bisphosphonates • MOA: inhibit bone resorption • less than 10% of an oral dose of these drugs is absorbed. • Food reduces absorption even further  empty stomach. • That’s why: pamidronate is not available as an oral preparation. • all currently available bisphosphonates have this complication (with the possible exception of etidronate) • Nearly half of the absorbed drug accumulates in bone; • C/I: Decreased renal function, esophageal motility disorders, and peptic ulcer disease are the main

  10. 3. Calcitonin: • ancillary treatment. • effect lasts for 6-10 hours. • Calcimar (salmon calcitonin) is available for parenteral & nasal administration (preferred) • MOA: (1) inhibits osteoclastic bone resorption ((although with time both resorption and firmation of bone are reduced) (2) In kidney: Reduces Ca and PO4 reabsorption • Useful for the treament of Paget’s disease, Hypercalcemia and osteoporossis

  11. 4. Gallium Nitrate (IV) • Acts by (-) bone resorption • Due to nephrotoxicity, patients should be well-hydrated & have good renal output before starting infusion

  12. 5. Plicamycin(Mithramycin):(risk of thrombocytopenia followed by hemorrhage), hepatic & renal toxicity 6. Phosphate: IV is hazardous procedure if not done properly: sudden hypocalcaemia, ectopic calcification, acute renal failure, hypotension • Must be given slowly (6-8 hrs) then switch to oral phosphate Very risky

  13. 7. Glucocorticoids: • Glucocorticoid hormones alter bone mineral homeostasis by: 1. antagonizing vitamin D-stimulated intestinal calcium transport, 2. by stimulating renal calcium excretion, and by 3. blocking bone formation • no clear role in acute treatment of hypercalcemia. • However, chronic hypercalcemia may respond within several days to glucocorticoid therapy • Prednisone (30-60 mg/day)

  14. HYPOCALCEMIA • Main features (neuromsucular): tetany, paresthesias, laryngospasm, muscle cramps, & convulsions • Major causes in adult: hypoparathyroidism, vitamin D deficiency, chronic kidney disease & malabsorption, infusions of citrated blood • Neonatal hypocalcemia usually resolves without therapy • Treatment: Ca & vitamin D (or its metabolites)

  15. Treatment of Hypocalcemia 1. Calcium: • IV: gluceptate, gluconate, chloride. Gluconate is the preferred form (less irritating to veins) • Rapid infusion can lead to cardiac arrhythmias • Oral: carbonate, lactate, phosphate, citrate Carbonate is preparation of choice: high % of Ca, ready availability, low cost, & antacid properties • Treatment: • Severe symptomatic hypocalcemia: slow infusion of 5-20 mL of 10% Cagluconate. Avoid rapid infusion (cardiac arrhythmias) • Less severe cases: oral Ca (carbonate to provide 400-1200mg of elemental Ca

  16. 2. Vitamin D 1,25(OH)2D3 (calcitriol), is the metabolite of choice for rapid action (↑serum Ca within 24-48 hrs). Also ↑ serum P but usually not observed early in treatment • Combined effects of calcitriol on both Ca & P make careful monitoring of serum Ca × P product important to avoid ectopic calcification

  17. HYPERPHOSPHATEMIA • Causes: renal failure, hypoparathyroidism & vitamin D intoxication • Emergency treatment: by dialysis or glucose & insulin infusions • Chronic treatment: 1.↓ dietary phosphate 2. Ca supplements 3. Al(OH)3-containing antacids (potential to induce Al-associated bone disease) 4. Phosphate-binding gels (Sevelamer)

  18. Diet Management of hyperphosphatemia • Minimize (but not avoid: cheese (no more than 1 oz per day, milk (250 mL per day), egg (no more than 1 per day- maximum 3-4 per week), heart, liver, kidney (no more than once per fortnight • Avoid: Pilchards, Sardines, Kippers, Herrings, Whitebait, Sprats, Fish Roe, Prawns or Crab, All Bran., Cocoa powder, Horlicks and Ovaltine, Evaporated milk, Chocolate (especially milk) and Fudge, Chocolate spread, Peanut butter, Nuts, popcorn.

  19. Hypophosphatemia • Causes: e.g. hyperparathyroidism, vitamin D deficiency, idiopathic hypercalciuria, vitamin D-resistant rickets, various other forms of renal phosphate wasting • Leads to: • reduction in the intracellular levels of ATP, • interfere with normal hemoglobin-to-tissue oxygen transfer, and • Rhabdomyolysis • Treatment: Depending on the clinical situation, replacement options include dietary phosphate, oral phosphate preparations, and IV phosphate


  21. NUTRITIONAL VITAMIN D DEFFICIENCY • Vitamin D deficiency in pediatric & geriatric populations on vegetarian diets & with ↓sunlight exposure • Prevention: 800-1200 units/d of vitamin D • Treatment: higher dosages (4000 units/d) •  25(OH)D No other metabolite is indicated • Diet should also contain adequate amounts of Ca & P

  22. CHRONIC RENAL FAILURE • Major problems: loss of 1,25(OH)2D & 24,25(OH)2D production, retention of P →↓ionized Ca levels → 2ry hyperparathyroidism • With loss of 1,25(OH)2D production, < Ca is absorbed from intestine & < bone is resorbed under influence of PTH → hypocalcemia→ exacerbation of hyperparathyroidism • Bones show mixture of osteomalacia & osteitisfibrosa • Less commonly hypercalcemia (adynamic bone disease)

  23. Use of Vitamin D Preparations • Vitamin D in patients with substantial degree of renal failure cannot be converted to its active metabolites • Two analogs of calcitriol, doxercalciferol & paricalcitol, are approved for the treatment of 2ry hyperparathyroidism of chronic renal failure. They are less likely to induce hypercalcemia

  24. Use of Vitamin D Preparations • 1,25(OH)2D3 (calcitriol) rapidly corrects hypocalcemia & at least partially reverses 2ry hyperparathyroidism & osteitisfibrosa. ↑ serum Ca in 1-2 days • Dihydrotachysterol, analog of 1,25(OH)2D, is equally effective. ↑Ca in 1-2 weeks • Neither calcitriol, nor dihydrotachysterol correct osteomalacia, & neither should be used in patients with hypercalcemia • Calcifediol (25[OH]D3) is < effective than calcitriol in stimulating intestinal calcium transport → < hypercalcemia • requires several weeks to restore normocalcemia

  25. INTESTINAL OSTEODYSTROPHY • Malabsorption of Ca & vitamin D →combination of osteoporosis & osteomalacia • Liver disease may: • ↓production of 25(OH)D from vitamin D • Impaired secretion into bile of vitamin D metabolites & conjugates → deplete body of endogenous vitamin D & metabolites • In mild forms of malabsorption, vitamin D can be used. In severe disease: calcitriol & calcifediol

  26. INTESTINAL OSTEODYSTROPHY • Malabsorption of Ca & vitamin D →combination of osteoporosis & osteomalacia • Liver disease may: • ↓production of 25(OH)D from vitamin D • Impaired secretion into bile of vitamin D metabolites & conjugates → deplete body of endogenous vitamin D & metabolites • In mild forms of malabsorption, vitamin D can be used. In severe disease: calcitriol & calcifediol

  27. OSTEOPOROSIS • Osteoporosis is abnormal loss of bone predisposing to fractures. • Occurs in: • postmenopausal women • older men • Chronic/long term glucocorticoids therapy • hyperparathyroidism • malabsorption syndrome

  28. Postmenopausal osteoporosis • may be accompanied by ↓1,25(OH)2D levels & ↓intestinal Ca transport • Estrogen deficiency → best treated with cyclic doses of estrogen • The most rapid loss of bone occurs within the first 5 years after menopause → administration of estrogens after this time may be < effective. • If estrogens are discontinued, accelerated bone loss may occur → treatment with estrogens should be started shortly after onset of menopause & may need to be continued for life

  29. Risk of endometrial carcinoma is minimized by addition of a progestin • Estrogen therapy may be reserved for women with ↓bone mineral content at the time of menopause or those who lose bone rapidly in the first year after it • Treatment may reinitiate menstrual bleeding. • Other complications: hypertension & thrombophlebitis • Small ↑risk (if it exists at all) of breast cancer is outweighed by ↓ risk of osteoporosis

  30. Vitamin D is often employed + dietary Ca supplementation • In several large studies, vitamin D supplementation (400-800 IU/d) has been shown to be useful • Calcitriol& its analog 1α(OH)D3↑bone mass & ↓ fractures • Use of these agents for osteoporosis is not FDA-approved, though they are used in other countries

  31. Fluoride: the only agent that can directly (+) bone formation →↑ bone density • Calcitonin is approved for use in treatment of postmenopausal osteoporosis. Reduces bone resorption • Bisphosphonates: Alendronate & most recently, risedronate, are approved for treatment of osteoporosis • Raloxifene, SERM, without adverse effects on breast or uterus, has been approved for prevention (not treatment) of osteoporosis Like estrogen, ↑bone density & ↓fractures in spine. However, ↑risk of thrombophlebitis

  32. PAGET'S DISEASE OF BONE • This is a disease of bone that initially results in the excessiveresorption of bone (by osteoclasts) followed by the replacement of normalbone marrow with vascular and fibrous tissue. • Manypatients are asymptomatic and diagnosed by routine X-rays. • The goal of treatment: ↓ bone pain & prevent progressive deformity, hearing loss, high-output cardiac failure, & immobilization hypercalcemia • Calcitonin & bisphosphonates are DOC • Treatment failures may respond to plicamycin (highly toxic)

  33. Paget’s disease of bone

  34. Calcitonin is administered intranasally, SC or IM • Sodium etidronate, alendronate, risedronate, & tiludronate are bisphosphonates currently approved for this condition in the USA • Pamidronate is used in other countries • Etidronate, but not pamidronate & alendronate can cause osteomalacia & ↑incidence of fractures • Alendronate & newer bisphosphonates cause gastric irritation when used at high doses